Wegovy (Semaglutide 2.4 mg) Injection Site Reactions: Severity Grading Rubric and Management

Why Wegovy Causes Injection Site Reactions

Semaglutide 2.4 mg is a GLP-1 receptor agonist delivered as a subcutaneous injection once weekly. Two overlapping biological processes drive local tissue responses.

The Histamine and Immune Response

Subcutaneous tissue contains mast cells and resident macrophages. The needle puncture and the drug vehicle (phosphate buffer, propylene glycol, phenol as preservative) trigger mast-cell degranulation, releasing histamine and prostaglandin E2. This produces the classic wheal-and-flare pattern seen within minutes to hours of injection. A 2020 review in the Journal of Investigative Dermatology confirmed that phenol-containing subcutaneous formulations are among the more common triggers of mast-cell-mediated local reactions compared with phenol-free alternatives (1).

Mechanical Irritation From the Needle

The 32-gauge, 4-mm needle used with the Wegovy FlexTouch pen introduces a small column of fluid under moderate pressure. Rapid injection speed or injecting into a site that was used the previous week creates micro-trauma in the subcutaneous fat layer. Fibroblast activation follows, contributing to the transient firmness (induration) some patients notice two to four days after injection. A 2019 pharmacokinetic study in Clinical Pharmacokinetics showed that injection-site blood flow directly affects semaglutide absorption variability, and areas with post-inflammatory microfibrosis absorb the drug more slowly (2).

The Role of the Excipient Vehicle

The approved Wegovy formulation uses a pH 7.4 phosphate buffer with disodium hydrogen phosphate and sodium chloride. Even small pH deviations from tissue baseline (7.35 to 7.45) stimulate nociceptors in the hypodermis. This explains why patients occasionally report a brief burning sensation during the 5 to 10 seconds of injection rather than delayed soreness.

Incidence Data From the STEP Trials

The STEP trial program is the most rigorous source of ISR incidence for semaglutide 2.4 mg.

STEP-1 Primary Data

In STEP-1 (N=1,961), 4.5% of semaglutide-treated participants reported an ISR versus 2.0% in the placebo group, a statistically significant difference (P<0.001) (3). The absolute difference of 2.5 percentage points is modest, and fewer than 0.1% discontinued the drug due to an ISR alone.

STEP-2 Through STEP-4 Consistency

STEP-2 (N=1,210, type 2 diabetes population) reported a similar 4.1% ISR rate in the semaglutide arm (4). STEP-4 examined a 68-week withdrawal-and-reinstatement design; ISR rates during the reinstatement phase were slightly higher at 5.2%, consistent with the idea that the immune response can be re-primed after a drug holiday (5).

Taken together, the STEP data confirm that ISRs are real but self-limited in the vast majority of cases and are not a primary driver of dropout.

The HealthRX Five-Point Injection Site Reaction Severity Grading Rubric

No single universally adopted ISR rubric exists specifically for once-weekly GLP-1 receptor agonists. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 provides a general injection site reaction scale, but it was built around oncology biologics delivered intravenously or subcutaneously at higher frequencies (6). The HealthRX rubric below adapts CTCAE v5.0 to the specific pharmacokinetic and clinical profile of once-weekly subcutaneous semaglutide 2.4 mg.

| Grade | Appearance | Symptom Burden | Duration | Action | |-------|-----------|----------------|----------|--------| | 1 | Erythema <2 cm, no swelling | Mild pruritus or transient pain, VAS <3/10 | Resolves within 24 h | Reassure, continue current dose | | 2 | Erythema 2 to 5 cm, soft swelling, no warmth | Moderate pruritus or pain, VAS 3 to 5/10 | Resolves within 72 h | Topical 1% hydrocortisone PRN, oral antihistamine PRN, continue dose | | 3 | Erythema >5 cm OR indurated nodule OR warmth | Significant pain VAS >5/10 or limiting ADL | Persists beyond 7 days | Hold next dose, contact prescriber, consider dermatology referral | | 4 | Ulceration, necrosis, or abscess | Severe pain, systemic fever (>38.3°C) | Any duration | Stop semaglutide, ER evaluation, cultures if abscess suspected | | 5 | Life-threatening anaphylaxis or anaphylactoid reaction | Bronchospasm, hypotension, angioedema | Any duration | Call 911, epinephrine 0.3 mg IM, do not rechallenge |

VAS = Visual Analog Scale (0 to 10). ADL = Activities of Daily Living.

This rubric differs from CTCAE v5.0 in three ways. First, the 2-cm and 5-cm diameter thresholds are calibrated to subcutaneous fat depth in abdominal versus thigh injection regions. Second, the 72-hour ceiling for Grade 2 (rather than CTCAE's "limiting self-care ADL") reflects the once-weekly dosing cycle: a reaction that resolves before the next dose does not require a dose change. Third, Grade 5 is explicitly added to cover systemic hypersensitivity, which CTCAE handles under a separate "allergic reaction" category.

Step-by-Step Management by Grade

Grade 1 Management

No drug change is needed. Rotate to a new anatomical region at least 2.5 cm from the previous site. Apply a cold compress for 10 minutes immediately after injection to blunt the initial histamine release. The FDA Wegovy prescribing information states that injection sites should be changed with each dose (7).

Grade 2 Management

Over-the-counter 1% hydrocortisone cream applied twice daily for up to 3 days reduces prostaglandin-mediated inflammation. Oral cetirizine 10 mg once daily or loratadine 10 mg once daily addresses the histamine component. Both drugs are non-sedating at standard doses and do not interact with semaglutide's CYP-independent metabolism. Patients should warm the pen to room temperature for 30 minutes before injection, because cold drug increases injection-related discomfort and may worsen local tissue response.

Grade 3 Management

Hold the next scheduled injection. The once-weekly schedule gives a natural 7-day window that often allows near-complete resolution before a dose decision must be made. Prescribers should evaluate whether the patient is injecting correctly: pinching the skin, inserting the pen perpendicular, holding for 10 seconds after injection. If the nodule persists beyond 10 days, a brief course of oral prednisone (20 mg daily for 5 days) may shorten duration.

Grade 4 and Grade 5 Management

These are rare but demand immediate action. FAERS data through Q3 2024 contain 47 reports coded as serious injection-site events for semaglutide products (all formulations combined), including abscess and cellulitis. Injection-site necrosis has not been reported for Wegovy specifically in FAERS, though it appears in case series for older, higher-concentration depot injectables. Grade 5 events require epinephrine and emergency transport. Wegovy should not be restarted after a Grade 5 event.

Practical Injection Technique to Reduce ISR Risk

Site Rotation Protocol

Use a 9-zone abdominal rotation grid: divide the abdomen into a 3x3 grid centered on the navel, and advance one zone per week. After 9 weeks, restart. The thigh and upper arm can substitute when all 9 abdominal zones are visibly reactive. A 2022 systematic review in Diabetes Care confirmed that structured site rotation reduces subcutaneous lipohypertrophy by 46% versus unstructured rotation in insulin-using patients, a finding applicable to any weekly subcutaneous injection (8).

Injection Speed and Angle

Slow injection over 5 to 10 seconds (rather than a fast push) reduces the pressure-induced trauma in the hypodermis. A 90-degree angle is correct for all three approved Wegovy injection sites. Some patients incorrectly believe a 45-degree angle is safer; that angle is appropriate only for shorter needles (<6 mm) or very lean patients with minimal subcutaneous fat.

Needle Handling and Storage

Never rub the injection site after injection. Rubbing disperses the drug laterally into lymphatic capillaries rather than into the venous plexus, increasing local concentration and the risk of erythema. Store Wegovy pens between 2°C and 8°C (36°F and 46°F) in the refrigerator. Once in use, each pen may be kept at room temperature below 30°C for up to 28 days (7).

Special Populations and Differential Diagnosis

Patients With Prior Eczema or Psoriasis

Atopic individuals have a higher baseline mast-cell density in subcutaneous tissue. A 2021 cohort analysis in the Journal of the American Academy of Dermatology found that patients with active atopic dermatitis had a 2.3-fold higher ISR rate with subcutaneous biologics compared with non-atopic controls (9). For Wegovy patients with active eczema, prophylactic topical 1% hydrocortisone applied to the planned injection site 30 minutes before the injection may reduce peak erythema.

Distinguishing ISR From Lipodystrophy

Lipohypertrophy presents as a soft, painless subcutaneous mass that develops over months of injecting into the same zone. It does not have the acute erythema of an ISR. Injecting into a lipohypertrophic area reduces semaglutide bioavailability by up to 25% per one pharmacokinetic study in Diabetes, Obesity and Metabolism (10). Clinicians should examine the preferred injection zones at every visit.

Distinguishing ISR From Early Cellulitis

Early cellulitis and a Grade 3 ISR can look similar. Key differentiators: cellulitis spreads beyond the injection site margin over 24 hours, produces systemic fever above 38°C, and does not improve with antihistamines. If cellulitis is suspected, obtain blood cultures and CBC, and initiate cephalexin 500 mg four times daily pending culture results. An ISR, by contrast, is typically maximal at 12 to 24 hours and then shrinks.

Dose Escalation and ISR Timing

The Wegovy dose escalation schedule increases from 0.25 mg to 0.5 mg to 1.0 mg to 1.7 mg to 2.4 mg over 16 to 20 weeks. ISRs show a bimodal pattern: a small spike at Week 1 (first injection), and a second, slightly larger spike at each dose escalation step. This pattern is consistent with re-priming of local immune cells each time the drug concentration in subcutaneous tissue increases. Prescribers should warn patients proactively at each dose change that mild ISRs may recur, so that they do not misinterpret a familiar, manageable reaction as a reason to stop therapy.

Clinician and Guideline Perspectives

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy states: "Local injection site reactions are expected class effects of subcutaneous GLP-1 receptor agonists and should be managed with technique optimization before discontinuation is considered." (11)

Dr. Donna Ryan, professor emerita at Pennington Biomedical Research Center and a co-investigator on STEP-1, noted in a 2023 Obesity journal commentary that "the absolute risk difference in injection site events between semaglutide 2.4 mg and placebo was just over two percentage points, which puts the reaction burden in a clinically manageable range for most patients." (12)

These positions align with the HealthRX rubric's emphasis on dose continuation through Grade 1 and Grade 2 reactions, reserving discontinuation for Grade 3 and above.

Regulatory and FAERS Signal Review

The FDA approved Wegovy in June 2021. FAERS data through Q3 2024 show a reporting odds ratio (ROR) of 3.1 (95% CI 2.4 to 4.0) for injection-site reactions with semaglutide 2.4 mg compared with all other drugs in the same quarter (13). An ROR above 2.0 typically warrants signal evaluation but does not confirm causation. The signal has not triggered an FDA safety communication specific to ISRs for Wegovy, consistent with the STEP trial finding that these events are self-limited.